The existing literature on plasma GFAP is rather limited but has so far unanimously suggested that plasma GFAP is an early marker of amyloid-β pathology, based predominantly on cross-sectional data of individuals with sporadic AD [17, 46, 47]. This evidence concerns the gene GFAP and Alzheimer disease.